(Q41386664)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claudio Gasperini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Diego Centonze

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Antonio Bertolotto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Luca Prosperini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Marco Capobianco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ruggero Capra

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Fabio Buttari

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Simonetta Galgani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Claudio Solaro

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Carlo Pozzilli

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Angelo Ghezzi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

19 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

1713-1722

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Bridging, switching or drug holidays - how to treat a patient who stops natalizumab?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Risk acceptance in multiple sclerosis patients on natalizumab treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Three years of experience: the Italian registry and safety data update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

What to expect after natalizumab cessation in a real-life setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Are quantitative functional measures more sensitive to worsening MS than traditional measures?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458515570768

21 January 2018

Identifiers

DOI

10.1177/1352458515570768

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25698174%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference